A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy

BACKGROUND & AIMS: NS3/4A protease inhibitors, boceprevir or telaprevir, combined with peginterferon and ribavirin was the standard treatment for HCV genotype 1 and remains the only available direct antiviral drug based therapy in some countries. Efficacy and safety data in liver transplant reci...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hepatol
Asıl Yazarlar: Burton, James R., O’Leary, Jacqueline G., Verna, Elizabeth C., Saxena, Varun, Dodge, Jennifer L., Stravitz, Richard T., Levitsky, Joshua, Trotter, James F., Everson, Gregory T., Brown, Robert S., Terrault, Norah A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394742/
https://ncbi.nlm.nih.gov/pubmed/24801415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2014.04.037
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller